WO2004056353A3 - Device and method for delivering mmp inhibitors - Google Patents
Device and method for delivering mmp inhibitors Download PDFInfo
- Publication number
- WO2004056353A3 WO2004056353A3 PCT/EP2003/014602 EP0314602W WO2004056353A3 WO 2004056353 A3 WO2004056353 A3 WO 2004056353A3 EP 0314602 W EP0314602 W EP 0314602W WO 2004056353 A3 WO2004056353 A3 WO 2004056353A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- delivering
- mmp inhibitors
- local administration
- optionally
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
- A61L2300/434—Inhibitors, antagonists of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003294917A AU2003294917A1 (en) | 2002-12-20 | 2003-12-19 | Device and method for delivering mmp inhibitors |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0229896A GB0229896D0 (en) | 2002-12-20 | 2002-12-20 | Organic compounds |
GB0229891.7 | 2002-12-20 | ||
GB0229895A GB0229895D0 (en) | 2002-12-20 | 2002-12-20 | Organic compounds |
GB0229891A GB0229891D0 (en) | 2002-12-20 | 2002-12-20 | Organic compounds |
GB0229896.6 | 2002-12-20 | ||
GB0229895.8 | 2002-12-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004056353A2 WO2004056353A2 (en) | 2004-07-08 |
WO2004056353A3 true WO2004056353A3 (en) | 2004-11-04 |
Family
ID=32685758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/014602 WO2004056353A2 (en) | 2002-12-20 | 2003-12-19 | Device and method for delivering mmp inhibitors |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003294917A1 (en) |
WO (1) | WO2004056353A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9403775B2 (en) | 2003-04-24 | 2016-08-02 | Incyte Corporation | AZA spiro alkane derivatives as inhibitors of metalloproteases |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2043736A4 (en) * | 2006-07-13 | 2010-03-17 | St Jude Medical | An implantable cardiac stimulation drug releasing electrode |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996000214A1 (en) * | 1994-06-24 | 1996-01-04 | Ciba-Geigy Ag | Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors |
WO1997022587A1 (en) * | 1995-12-15 | 1997-06-26 | Novartis Ag | Alpha-substituted arylsulphonamido hydroxamic acids as tnf-alpha and matrix metalloproteinase inhibitors |
WO1998007697A1 (en) * | 1996-08-23 | 1998-02-26 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
WO1998014424A1 (en) * | 1996-10-02 | 1998-04-09 | Novartis Ag | Hydroxamic acid derivatives |
WO1998042662A1 (en) * | 1997-03-20 | 1998-10-01 | Novartis Ag | Certain cyclic thio substituted acylaminoacid amide derivatives |
WO2000056283A1 (en) * | 1999-03-24 | 2000-09-28 | The B.F.Goodrich Company | Inhibition of matrix metalloproteinases with polymers and pharmaceutical applications thereof |
US6194451B1 (en) * | 1997-01-31 | 2001-02-27 | Pharmacia & Upjohn S.P.A. | Matrix metalloproteinase inhibitors |
EP1088550A1 (en) * | 1999-10-01 | 2001-04-04 | Pfizer Products Inc. | alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders |
WO2002055121A1 (en) * | 2001-01-11 | 2002-07-18 | Biocompatibles Uk Limited | Drug delivery from stents |
-
2003
- 2003-12-19 WO PCT/EP2003/014602 patent/WO2004056353A2/en not_active Application Discontinuation
- 2003-12-19 AU AU2003294917A patent/AU2003294917A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996000214A1 (en) * | 1994-06-24 | 1996-01-04 | Ciba-Geigy Ag | Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors |
WO1997022587A1 (en) * | 1995-12-15 | 1997-06-26 | Novartis Ag | Alpha-substituted arylsulphonamido hydroxamic acids as tnf-alpha and matrix metalloproteinase inhibitors |
WO1998007697A1 (en) * | 1996-08-23 | 1998-02-26 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
WO1998014424A1 (en) * | 1996-10-02 | 1998-04-09 | Novartis Ag | Hydroxamic acid derivatives |
US6194451B1 (en) * | 1997-01-31 | 2001-02-27 | Pharmacia & Upjohn S.P.A. | Matrix metalloproteinase inhibitors |
WO1998042662A1 (en) * | 1997-03-20 | 1998-10-01 | Novartis Ag | Certain cyclic thio substituted acylaminoacid amide derivatives |
WO2000056283A1 (en) * | 1999-03-24 | 2000-09-28 | The B.F.Goodrich Company | Inhibition of matrix metalloproteinases with polymers and pharmaceutical applications thereof |
EP1088550A1 (en) * | 1999-10-01 | 2001-04-04 | Pfizer Products Inc. | alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders |
WO2002055121A1 (en) * | 2001-01-11 | 2002-07-18 | Biocompatibles Uk Limited | Drug delivery from stents |
Non-Patent Citations (3)
Title |
---|
FINK C A ET AL: "Design and synthesis of thiol containing inhibitors of matrix metalloproteinases", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, no. 2, 18 January 1999 (1999-01-18), pages 195 - 200, XP004152599, ISSN: 0960-894X * |
GOBELL F ET AL: "BIODIVYSIO STENT COATED WITH METALLOPROTEINASE INHIBITOR REDUCES NEOIN", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 104, no. 17, SUPPL II, 23 October 2001 (2001-10-23), pages II - 388, XP009028065, ISSN: 0009-7322 * |
KOTTIRSCH GEORG ET AL: "beta-Aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 11, 23 May 2002 (2002-05-23), pages 2289 - 2293, XP002290121, ISSN: 0022-2623 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9403775B2 (en) | 2003-04-24 | 2016-08-02 | Incyte Corporation | AZA spiro alkane derivatives as inhibitors of metalloproteases |
Also Published As
Publication number | Publication date |
---|---|
AU2003294917A1 (en) | 2004-07-14 |
WO2004056353A2 (en) | 2004-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002089791A3 (en) | Acne treatment with lipooxigenase inhibitors | |
MY143407A (en) | Indazole derivatives as inhibitors of hormone sensitive lipase | |
WO2003061584A3 (en) | Novel substituted benzimidazole dosage forms and method of using same | |
WO2004093826A3 (en) | Compositions of cyclooxygenase-2 selective inhibitors and 5-ht1b/1d agonists for the treatment and prevention of migraine | |
WO2003065988A3 (en) | A combination for treating cold and cough | |
CY1108725T1 (en) | Combination of NMDA antagonist and acetylcholinesterase inhibitors for the treatment of ALZHEIMER | |
CA2396159A1 (en) | Novel substituted benzimidazole dosage forms and method of using same | |
AU2003240949A1 (en) | Active agent delivery systems and methods for protecting and administering active agents | |
HUP0400194A3 (en) | Imidazolidindion derivatives as metalloproteinase inhibitors, their use and pharmaceutical compositions containing them | |
PL1727551T3 (en) | Pharmaceutical composition comprising a benzodiazepine derivative and a inhibitor of the rsv fusion protein | |
WO2005011586A3 (en) | Treatment and preventi0n of cardiovascular events | |
PL1727550T3 (en) | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | |
NO20054607L (en) | Nitrogen-containing heterocyclic derivative having 2,6-disubstituted styryl | |
WO2002008217A3 (en) | COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS | |
HUP0400193A3 (en) | Imidazolindion derivatives as metalloproteinase inhibitors, their use and pharmaceutical compositions containing them | |
WO2001052897A3 (en) | Therapeutic anti-inflammatory and analgesic composition containing selective cox-2 inhibitors | |
WO2007022509A3 (en) | Use of seh inhibitors as analgesics | |
WO2004009583A3 (en) | Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor | |
WO2008042480A3 (en) | Epoxide inhibitors of cysteine proteases | |
NO20054216L (en) | Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention | |
TW200733963A (en) | Cough inhibitor | |
AU2001255393A1 (en) | Halogentated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors | |
SE0300445D0 (en) | New combination | |
ZA200502909B (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2. | |
AU2003258630A1 (en) | Pyrimidine derivatives as selective cox-2 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NI NO NZ OM PG PH PL PT RO RU SC SE SG SK SY TJ TM TN TR TT UA US UZ VC VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |